Results 181 to 190 of about 638,552 (336)

Cold Activation of the Classical Complement Pathway found in the Patients with Chronic Liver Diseases [PDF]

, 1976
Hajime Kitamura, K Nagaki, Shinya Inai
openalex   +1 more source

Functional Connectivity Associations With Markers of Disease Progression in GRN Pathogenic Variant Carriers

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Autosomal dominant progranulin (GRN) pathogenic variants are a genetic cause of frontotemporal lobar degeneration. Though clinical trials for GRN‐related therapies are underway, there is an unmet need for biomarkers that can predict symptom onset and track disease progression.
Taru M. Flagan, Stephanie A. Chu, Suvi Häkkinen, Liwen Zhang, David McFall, Jonathan D. Rohrer, Jesse A. Brown, Alex J. Lee, Kristen Fernhoff, Lorenzo Pasquini, Katherine P. Rankin, Maria Luisa Mandelli, Maria Luisa Gorno‐Tempini, Jennifer S. Yokoyama, Virginia E. Sturm, Brian Appleby, Bradford C. Dickerson, Kimiko Domoto‐Reilly, Tatiana Foroud, Daniel H. Geschwind, Nupur Ghoshal, Neill R. Graff‐Radford, Ging‐Yuek Robin Hsiung, Eric J. Huang, Edward Huey, Kejal Kantarci, Irene Litvan, Ian R. Mackenzie, Mario F. Mendez, Chiadi U. Onyike, Leonard Petrucelli, Eliana Marisa Ramos, Erik D. Roberson, Julio C. Rojas, Maria Carmela Tartaglia, Arthur W. Toga, Sandra Weintraub, Leah K. Forsberg, Hilary W. Heuer, Brad F. Boeve, Adam L. Boxer, Howard J. Rosen, Bruce L. Miller, Fermin Moreno, William W. Seeley, Suzee E. Lee, on behalf of the ALLFTD Consortium   +46 more
wiley   +1 more source

The Capacity of Lymphoblastoid Cells to Activate the Alternative Complement Pathway Is Correlated with their Transformation by Epstein-Barr Virus [PDF]

, 1978
I. McConnell, P. J. Lachmann, Thomas F. Lint, George Klein   +3 more
openalex   +1 more source

Complement activation in thrombotic thrombocytopenic purpura [PDF]

, 2014
Alvarez-Larran, Burns, Camous, Castellheim, Cat, Csuka, Dang, Ferrari, Ferrari, Ferrari, Galbusera, Gombos, Lotta, Lucisano Valim, Mitra, Moake, Monsinjon, Nauta, Noris, Ruiz-Torres, Sadler, Sims, Tedesco, Tsai, Valant, Wiedmer, Wright, Wu, Zwart   +28 more
core   +1 more source

Longitudinal Study of Salivary Biomarkers in the Definition of Clinico‐Molecular Progression of Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
Longitudinal changes in salivary biomarkers in Parkinson’s disease (PD) from early (T0) to 4‐year follow‐up (T1), quantified by ELISA: oligomeric and total α‐synuclein, total and phosphorylated tau, MAP1LC3B (autophagy), and TNFa (inflammation). Blue arrows indicate direction of change at T1 vs T0 (up = increase; down = decrease).
Maria Ilenia De Bartolo, Daniele Belvisi, Matteo Costanzo, Claudia Caturano, Francesco Emanuele Bellomi, Carolina Cutrona, Flavia Aiello, Giorgio Leodori, Massimo Marano, Romina Mancinelli, Antonella Conte, Giovanni Fabbrini, Alfredo Berardelli, Giorgio Vivacqua   +13 more
wiley   +1 more source

COMPLEMENT ACTIVITY IN PNEUMONIA 1 [PDF]

Journal of Clinical Investigation, 1942
William H. Walker, David D. Rutstein
openaire   +3 more sources

Long COVID in People With Multiple Sclerosis and Related Disorders: A Multicenter Cross‐Sectional Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Managing long COVID in people with multiple sclerosis and related disorders (pwMSRD) is complex due to overlapping symptoms. To address evidence gaps, we evaluated long COVID susceptibility in pwMSRD versus controls and its associations with multi‐domain function and disability.
Chen Hu, Jiyeon Son, Lindsay McAlpine, Elizabeth L. S. Walker, Megan Dahl, Emily Song, Sugeidy Ferreira Brito, Katelyn Kavak, Kaho Onomichi, Amit Bar‐Or, Christopher Perrone, Claire S. Riley, Bianca Weinstock‐Guttman, Philip L. De Jager, Erin E. Longbrake, Zongqi Xia   +15 more
wiley   +1 more source

Alternative Pathway of Complement Activation in Full Term and Premature Infants

, 1979
Robert C. Strunk, Lawrence J. Fenton, John A. Gaines   +2 more
openalex   +1 more source

Analysis of Soluble Interleukin‐2 Receptor as a Prognostic Biomarker in NMOSD and MOGAD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Soluble interleukin‐2 receptor (sIL‐2R) is a biomarker for T cell activity. T cells are involved in neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD) pathogenesis. However, sIL‐2R has so far not been evaluated in these conditions.
Philipp Klyscz, Carolin Otto, Klemens Ruprecht, Susanna Asseyer, Hannes Ole Tiedt, Christian Meisel, Judith Bellmann‐Strobl, Friedemann Paul, Patrick Schindler   +8 more
wiley   +1 more source

Proteomic profiling links complement activation to thrombosis in JAK2V617F myeloproliferative neoplasms. [PDF]

Transl Oncol
De Moner B, Martinez-Sanchez J, Escribano-Serrat S, Ramos A, Moreno-Castaño AB, Arellano-Rodrigo E, Escolar G, Carreras E, Álvarez-Larrán A, Diaz-Ricart M.   +9 more
europepmc   +1 more source